Thanks for the reply, the only reason I asked was that if they do manage to continue to make good progress and they need to raise money would there not be a big buyer ready to step in. Just my thoughts. GLA
Pardon me for my ignorance, but which is the best way to find out the total amont of share for SAR, and the amount that are not held by anyone, and the amount that are available to buy (might sound a bit long winded) Thanks in anticipation.
I tried to register but to find out if in an experts opinion the SAR TYK2 patent is better than two registered by Takeda for TYK2 but it's a pay per view site so no more info available on this at the moment.
But if you consider the size difference between the two companies, just having the comparison is a plus for SARs TYK2 programme. It might prove to be better but I guess we will just have to wait until more information comes out.
Not sure which way they are going. Doing it in parallel is quicker but the serial approach would be cheaper (as you stop is something goes wrong before moving on to the next step). Either way a failure would be price sensitive and
Correct me if i am wrong, or if i am looking at it wrongly. but If all the tests that are being carried out at the same time, as opposed to one after the other, is it safe to assume that no problems have arisen, and that everything is on course for a satisfactory conclusion. Just my thoughts GLA
April is a busy month for Tim. He's at the AACR meeting in San Diego from the 6th to the 10th then in Paris for the TTS Europe meeting on 14/15th (shareholder funded jollies comments to come, I'm sure but these are necessary meetings he needs to attend IMO).
In the Research Update it did contain this line in relation to the SRI collaboration for TYK2....
"We are planning to publish the results of our studies in scientific literature and present them at conferences during 2014"
Whilst TYK2 is not a cancer programme (this rules out the AACR meeting) TTS is a licencing and partnering type so it is possible we could see some of the "scientific literature" released soon and it could be presented here.
According to the Events section of the website, the next opportunity after TTS where this could be presented are October (BIA UK), November (BIO Europe) or December (Genesis).
From re-reading this section of the update again, the results so far do seem favourable. There was no need to say that they would be published ( you don't publish failures) so hopefully it will be the TTS. He also mentioned that other JAK1 kinase drugs had resulted in valuable licencing deals for others.
Hopefully this will come off soon. The size of any potential deal is a bit irrelevant. More cash is better, but if he can get enough to cover the CHK1 costs it takes away the biggest immediate risk (providing it gets that far) for SAR in the short term - paying for their share of the trials without another placing.
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.